Hip Dysplasia, Postoperative Complications
Conditions
Brief summary
The aim of this study is to investigate the effect of a single preoperative high-dose steroid injection on complications in the immediate postoperative phase after periacetabular osteotomy. Primary outcome is the proportion of patients who have moderate to severe postoperative pain in the post anaesthesia care unit. Secondary outcomes are organspecific complications in the post anaesthesia phase, pain and nausea the first 5 days, wound infection and readmissions the first 30 days after surgery. The investigators hypothesize that the frequency of moderate to severe pain and organspecific complications in the post anaesthesia care unit will be lower among patients receiving high dose dexamethasone. The investigators hypothesize, that there will be no difference in wound infections or readmissions.
Detailed description
Post-surgery, patients are traditionally observed and treated in post-anesthesia care units (PACU) until they are discharged to the ward (or directly home) assessed by standardized international discharge criteria. The research project Why in PACU? (Rigshospitalet, Denmark), has since the beginning of 2016 systematically collected and analyzed procedure-related complications in the recovery phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems, orthostatic intolerance and cognitive disorders. Common to all the above-mentioned post-operative problems are the possible links to the inflammatory response caused by the surgical trauma. Glucocorticoids can in this context be central for the reduction of acute postoperative organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical procedures, single dose, pre-operative glucocorticoids have been shown to reduce post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as accelerate the convalescence. Meta-analyses also showed that single-dose administration of glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as opposed to long-term treatment. The Why in PACU? database shows that 70 % of patients experience moderate to severe pain in the immediate postoperative phase. This is despite a multimodal analgesic regime with preoperative analgesics and local analgesic catheter in the surgical site. Opioids are frequently administered to relieve pain, resulting in sedation, risk of hypoxia and delaying mobilization. Patients having Ganz osteotomy are primarily young women with hipdysplasia, that are otherwise healthy. Lenght of stay is typically 5 days, due to pain and lack of mobilisation. In this study patients are randomized to either high dose (48 mg) or standard/low dose (8 mg) dexamethasone, administered preoperatively. The hypothese is that patients receiving high dose dexamethasone will experience less pain in the immediate postoperative course and receive less opioids. The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV have been shown in numerous trials, and is already being administered to all patients at the clinic. It would therefore not be ethically correct to withdraw from this practise.
Interventions
intravenous
Sponsors
Study design
Eligibility
Inclusion criteria
* planned unilateral periacetabular osteotomy * informed signed consent
Exclusion criteria
* Chronic/ongoing (\<30 days) use of glucocorticoids (except inhalation therapy) * ongoing (\<30 days) use of immunosuppressive therapy * insulin dependent diabetes * pregnancy/breastfeeding * allergies toward study medication, or medication in the standard treatment * surgery cannot be performed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Moderate to Severe Postoperative Pain | 12 hours | Moderate to severe pain (NRS \> 3) in the post-anesthesia care unit (PACU) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lenght of Stay, Hospital | 1 week | Total lenght of stay, Hospital |
| Pain Scores, PACU | 12 hours | Differences between groups in maximal and average pain score during PACU stay. Pain scores are measured on a numeric rating scale (NRS), 0-10. 0 is no pain, 10 is worst pain imaginable. |
| Complications | 24 hours | Patients with complications requiring treatment the first 24 hours (PACU and ward) |
| Self Reported Postoperative Pain | postoperative day 0 to 4, once a day | Self-reported pain on a Numeric rating scale (NRS), NRS 0-10, 0 = no pain, 10= worst pain imaginable. Reported once daily, postoperative days 0 to 4 |
| Lenght of Stay, PACU | 24 hours | Total lenght of stay in PACU |
| Number of Patients With Sleep Problems | 4 days | Self-reported quality of sleep (days 0-4). Questionnaire. Results dichotomized to sleep problems (trouble falling asleep, frequent awakenings, no sleep) or no sleep problems. |
| Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | postoperative day 0 to 4, once a day | Self-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire |
| Number of Patients Readmitted to Hospital Within 30 Days | 30 days | Any readmission within 30 days |
| Number of Patients With Wound Infections Within 30 Days | 30 days | Any wound infections/complications |
| Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | postoperative day 0 to 4, once a day | Patients reporting PONV and/or receiving antiemetic medication on postoperative days 0 to 4 |
Countries
Denmark
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dexamethasone 48 mg Dexamethasone 48 mg pre-operative, single shot injection
Dexamethasone: intravenous | 32 |
| Dexamethasone 8 mg Dexamethasone 8 mg pre-operative, single shot injection
Dexamethasone: intravenous | 32 |
| Total | 64 |
Baseline characteristics
| Characteristic | Dexamethasone 48 mg | Dexamethasone 8 mg | Total |
|---|---|---|---|
| Age, Continuous | 28 years STANDARD_DEVIATION 8 | 29 years STANDARD_DEVIATION 7 | 29 years STANDARD_DEVIATION 8 |
| Bleeding | 467 ml STANDARD_DEVIATION 301 | 510 ml STANDARD_DEVIATION 295 | 500 ml STANDARD_DEVIATION 296 |
| Body Mass Index (BMI) | 23 kg/m^2 STANDARD_DEVIATION 3 | 23 kg/m^2 STANDARD_DEVIATION 3 | 23 kg/m^2 STANDARD_DEVIATION 3 |
| Comorbidities, none | 30 Participants | 27 Participants | 57 Participants |
| Daily intake of analgesics, preoperative | 4 Participants | 6 Participants | 10 Participants |
| Daily intake of opioids, preoperative | 2 Participants | 2 Participants | 4 Participants |
| Operating time | 71 minutes STANDARD_DEVIATION 20 | 69 minutes STANDARD_DEVIATION 13 | 70 minutes STANDARD_DEVIATION 17 |
| Previous operation (contralateral periacetabular osteotomy) | 3 Participants | 9 Participants | 12 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 27 Participants | 24 Participants | 51 Participants |
| Sex: Female, Male Male | 5 Participants | 8 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 32 | 0 / 32 |
| other Total, other adverse events | 0 / 32 | 0 / 32 |
| serious Total, serious adverse events | 1 / 32 | 0 / 32 |
Outcome results
Number of Participants With Moderate to Severe Postoperative Pain
Moderate to severe pain (NRS \> 3) in the post-anesthesia care unit (PACU)
Time frame: 12 hours
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dexamethasone 48 mg | Number of Participants With Moderate to Severe Postoperative Pain | 26 Participants |
| Dexamethasone 8 mg | Number of Participants With Moderate to Severe Postoperative Pain | 22 Participants |
Complications
Patients with complications requiring treatment the first 24 hours (PACU and ward)
Time frame: 24 hours
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dexamethasone 48 mg | Complications | 24 Participants |
| Dexamethasone 8 mg | Complications | 25 Participants |
Lenght of Stay, Hospital
Total lenght of stay, Hospital
Time frame: 1 week
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dexamethasone 48 mg | Lenght of Stay, Hospital | 78 hours |
| Dexamethasone 8 mg | Lenght of Stay, Hospital | 77 hours |
Lenght of Stay, PACU
Total lenght of stay in PACU
Time frame: 24 hours
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dexamethasone 48 mg | Lenght of Stay, PACU | 2 hours |
| Dexamethasone 8 mg | Lenght of Stay, PACU | 3 hours |
Number of Patients Readmitted to Hospital Within 30 Days
Any readmission within 30 days
Time frame: 30 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dexamethasone 48 mg | Number of Patients Readmitted to Hospital Within 30 Days | 1 Participants |
| Dexamethasone 8 mg | Number of Patients Readmitted to Hospital Within 30 Days | 3 Participants |
Number of Patients With Feelings of Anxiety, Unrest and/or Sadness
Self-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire
Time frame: postoperative day 0 to 4, once a day
Population: Missing data from questionnaires, missing at random
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 1 : restlessness | 3 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 2 : fatigue | 21 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 0 : restlessness | 11 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 3 : sadness | 9 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 1 : fatigue | 20 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 3 : restlessness | 9 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 1 : sadness | 6 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 3 : fatigue | 17 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 2 : sadness | 8 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 4 : sadness | 8 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 0 : fatigue | 23 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 4 : restlessness | 10 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 2 : restlessness | 6 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 4 : fatigue | 17 Participants |
| Dexamethasone 48 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 0 : sadness | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 4 : fatigue | 10 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 0 : sadness | 2 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 0 : restlessness | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 0 : fatigue | 21 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 1 : sadness | 4 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 1 : restlessness | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 1 : fatigue | 17 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 2 : sadness | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 2 : restlessness | 11 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 2 : fatigue | 14 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 3 : sadness | 6 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 3 : restlessness | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 3 : fatigue | 13 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 4 : sadness | 5 Participants |
| Dexamethasone 8 mg | Number of Patients With Feelings of Anxiety, Unrest and/or Sadness | Day 4 : restlessness | 3 Participants |
Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4
Patients reporting PONV and/or receiving antiemetic medication on postoperative days 0 to 4
Time frame: postoperative day 0 to 4, once a day
Population: Missing data day 4 due to discharge from hospital
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dexamethasone 48 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 1 | 6 Participants |
| Dexamethasone 48 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 3 | 7 Participants |
| Dexamethasone 48 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 2 | 9 Participants |
| Dexamethasone 48 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 4 | 3 Participants |
| Dexamethasone 48 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 0 | 7 Participants |
| Dexamethasone 8 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 4 | 2 Participants |
| Dexamethasone 8 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 0 | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 1 | 9 Participants |
| Dexamethasone 8 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 2 | 11 Participants |
| Dexamethasone 8 mg | Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4 | Day 3 | 4 Participants |
Number of Patients With Sleep Problems
Self-reported quality of sleep (days 0-4). Questionnaire. Results dichotomized to sleep problems (trouble falling asleep, frequent awakenings, no sleep) or no sleep problems.
Time frame: 4 days
Population: Missing data from questionnaires, missing at random, not filled out or not sent back
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dexamethasone 48 mg | Number of Patients With Sleep Problems | Day 1 | 9 Participants |
| Dexamethasone 48 mg | Number of Patients With Sleep Problems | Day 3 | 9 Participants |
| Dexamethasone 48 mg | Number of Patients With Sleep Problems | Day 2 | 8 Participants |
| Dexamethasone 48 mg | Number of Patients With Sleep Problems | Day 4 | 8 Participants |
| Dexamethasone 48 mg | Number of Patients With Sleep Problems | Day 0 | 13 Participants |
| Dexamethasone 8 mg | Number of Patients With Sleep Problems | Day 4 | 8 Participants |
| Dexamethasone 8 mg | Number of Patients With Sleep Problems | Day 0 | 12 Participants |
| Dexamethasone 8 mg | Number of Patients With Sleep Problems | Day 1 | 13 Participants |
| Dexamethasone 8 mg | Number of Patients With Sleep Problems | Day 2 | 9 Participants |
| Dexamethasone 8 mg | Number of Patients With Sleep Problems | Day 3 | 9 Participants |
Number of Patients With Wound Infections Within 30 Days
Any wound infections/complications
Time frame: 30 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dexamethasone 48 mg | Number of Patients With Wound Infections Within 30 Days | 0 Participants |
| Dexamethasone 8 mg | Number of Patients With Wound Infections Within 30 Days | 0 Participants |
Pain Scores, PACU
Differences between groups in maximal and average pain score during PACU stay. Pain scores are measured on a numeric rating scale (NRS), 0-10. 0 is no pain, 10 is worst pain imaginable.
Time frame: 12 hours
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dexamethasone 48 mg | Pain Scores, PACU | Average pain | 2 score on a scale (numeric rating scale) |
| Dexamethasone 48 mg | Pain Scores, PACU | Maximal pain | 5 score on a scale (numeric rating scale) |
| Dexamethasone 8 mg | Pain Scores, PACU | Average pain | 2 score on a scale (numeric rating scale) |
| Dexamethasone 8 mg | Pain Scores, PACU | Maximal pain | 5 score on a scale (numeric rating scale) |
Self Reported Postoperative Pain
Self-reported pain on a Numeric rating scale (NRS), NRS 0-10, 0 = no pain, 10= worst pain imaginable. Reported once daily, postoperative days 0 to 4
Time frame: postoperative day 0 to 4, once a day
Population: Missing data, missing at random
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dexamethasone 48 mg | Self Reported Postoperative Pain | Day 2 | 3 score on a scale | Standard Deviation 2 |
| Dexamethasone 48 mg | Self Reported Postoperative Pain | Day 1 | 4 score on a scale | Standard Deviation 2 |
| Dexamethasone 48 mg | Self Reported Postoperative Pain | Day 3 | 3 score on a scale | Standard Deviation 2 |
| Dexamethasone 48 mg | Self Reported Postoperative Pain | Day 4 | 3 score on a scale | Standard Deviation 2 |
| Dexamethasone 48 mg | Self Reported Postoperative Pain | Day 0 | 3 score on a scale | Standard Deviation 2 |
| Dexamethasone 8 mg | Self Reported Postoperative Pain | Day 4 | 3 score on a scale | Standard Deviation 2 |
| Dexamethasone 8 mg | Self Reported Postoperative Pain | Day 0 | 4 score on a scale | Standard Deviation 2 |
| Dexamethasone 8 mg | Self Reported Postoperative Pain | Day 1 | 4 score on a scale | Standard Deviation 2 |
| Dexamethasone 8 mg | Self Reported Postoperative Pain | Day 2 | 4 score on a scale | Standard Deviation 2 |
| Dexamethasone 8 mg | Self Reported Postoperative Pain | Day 3 | 3 score on a scale | Standard Deviation 2 |